Screener
BioCryst Pharmaceuticals BCRX Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:04 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053300
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Trade receivables | 110,757 | 106,818 |
| Inventory, net | 6,056 | 5,398 |
| Prepaid expenses and other current assets | 14,818 | 17,182 |
| Total current assets | 484,683 | 404,346 |
| Long-term inventory, net | 31,945 | 23,990 |
| Property and equipment, net | 9,058 | 8,783 |
| Long-term investments | — | 61,164 |
| Right of use assets, net | 12,608 | 10,203 |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's total current assets?
- BioCryst Pharmaceuticals (BCRX) reported total current assets of $484.68M in Q2 2026.
- How has BioCryst Pharmaceuticals's total current assets changed year-over-year?
- BioCryst Pharmaceuticals's total current assets increased by 21.6% year-over-year, from $398.46M to $484.68M.
- What is the long-term trend for BioCryst Pharmaceuticals's total current assets?
- Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's total current assets has grown at a 4.5% compound annual growth rate (CAGR), from $323.8M to $404.35M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about BioCryst Pharmaceuticals's total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude